BCLAF1 and neoplasm: BCLAF1 mutations were present across multiple tumor types; melanomas had the highest overall prevalence (14.4%), with bladder cancer (9.1%) and NSCLC (4.9%) also harboring BCLAF1 mutations (Fig. 3e, f).